Foreign Direct Investment (FDI) in Pharmaceutical Sector in India: Striking Balance Between Indigenous Needs and Foreign Investors’ Interest

Authors

  • Anil Kumar Angrish Associate Professor, Department of Pharmaceutical Management, National Institute of Pharmaceutical Education and Research (NIPER), Mohali
  • Sanjeev K. Bansal Assistant Professor, Department of Management, I.K.Gujral Punjab Technical University, Main Campus, Kapurthala

DOI:

https://doi.org/10.33516/maj.v56i4.58-61p

Keywords:

No Keywords.

Abstract

Indian pharmaceutical industry is predominantly driven by the private sector and the public sector has negligible role. Notable factor is that Indian pharma industry is ranked 3rd globally in terms of volume, and 14th in terms of value. This growth is attributed to changes made in the Patents Act, 1970, which replaced the Product Patent Act, 1911 which allowed process patent (product patent introduced again in 2005), changes in the Foreign Exchange Regulation Act, 1973 (now, Foreign Exchange Management Act) which compelled foreign companies to reduce their equity to 40% thereby reducing the number of subsidiaries of MNCs from ten (10) in 1973 to two (02) by 1985, among others. Indian pharmaceutical sector is one such sector that not only caters to domestic requirements but also exports to more than 200 countries/territories including highly regulated markets, e.g., USA. The present paper discusses various measures undertaken to protect indigenous pharmaceutical industry or consumers/patients but has implications for FDI. It also throws light on major developments in last one decade that had direct implications on the FDI in Pharmaceutical Sector in India, apart from considering the concerns of foreign investors.

Downloads

Download data is not yet available.

Published

2021-04-30

How to Cite

Angrish, A. K., & Bansal, S. K. (2021). Foreign Direct Investment (FDI) in Pharmaceutical Sector in India: Striking Balance Between Indigenous Needs and Foreign Investors’ Interest. The Management Accountant Journal, 56(4), 58–61. https://doi.org/10.33516/maj.v56i4.58-61p

Issue

Section

Cover Story

References

Cabinet approves Production Linked Incentive Scheme for Pharmaceuticals (2021February 24). Press Information Bureau.

Column: Poor pharma policy (2014, February 12). Financial Express.

Consolidated FDI Policy (effective from October 15, 2020). Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India.

Daiichi unveils Ranbaxy open offer (2008, June 17). Economic Times.

Das, Sohini (2020, February 25). Share of drugs under price control dips in domestic pharma market. Business Standard.

Datta, P T Jyothi (2019, June 05). Dwindling FDI in pharma, medical devices worries industry. Business Line.

Datta, PT Jyothi (2018, January 15). Price control fallout: Abbott withdraws two stents from India. Business Line.

FDI in drugs & Pharma sector rose to Rs. 2,065 cr in April-Sept FY20: Govt (2020, February 8). Economic Times.

How Indian pharma can grow to be a $ 100-bn industry (2020, September 11). Economic Times.

Implementation of GST to attract more FDI (2016, September 13). Economic Times.

Indian pharma exports miss target, stand at $20.58 bn in FY 20 (2020, May 8). Economic Times.

Indian pharma exports may cross $25 bn this fiscal (2020, November 23). Business Line.

Indian pharma market is expected to hit USD 130 billion by 2030: Sadananda Gowda (2021, February 8). Economic Times.

Jayakumar, PB (2019, July 14). FDI Drying up. Business Today.

Kulkarni, Mahesh (2021, January 29). Indian pharma sector set to grow 3 times in next decade, says Economic Survey. Deccan Herald.

Medtronic to withdraw latest stents from India after price cap (2018, January 15). Business Line.

Nadh P. Omkar (2018, December 27). India’s pharma industry: at a patent disadvantage. Deccan Herald.

National Pharmaceuticals Pricing Policy, 2012 (NPPP-2012) (2012, December 07) Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.

Narasimhan, T. E. (2019, June 9). Industry blames policies, USFDA probes for 73% drop in pharma FDI. Business Standard.

No non-competition clause in pharma FDI: RBI (2014, April 22). Business Standard.

NPPA fixes retail prices of 869 formulations & coronary stents under DPCO 2013 based on price revision as per annual WPI (2020, March 28). Pharmabiz.com.

NPPA rejects Abbott, Medtronic’s request to withdraw latest stents (2017, April 27). Economic Times.

One Hundred and Tenth Report on FDI in Pharmaceutical Sector (2013, August 13). Department related Parliamentary Standing Committee on Commerce, Rajya Sabha, Parliament of India.

Pharma exports grow 7.57% in FY20 (2020, May 8). The Hindu.

Price control on stents to continue: Govt (2018, February 22). Economic Times.

Porecha, Maitri (2020, January 31). Drug Price Control Order led medicines to become costlier: Economic Survey. Business Line.

Sharma, Samrat (20021, January 5). India’s pharma export shoots up amid coronavirus pandemic; ‘China plus one’ policy helps. Financial Express.

Suneja, Kirtika (2020, May 10). Mega FDI plan to focus on faster pharma approvals. Economic Times.

Thacker, Teena (2017, September 9). Abbott discontinues global sales of 1st – generation Absorb stents. Mint.

Thacker, Teena (2020, August 6). Govenment notifies over 450 Fixed-Dose Combination drugs as ‘rational’. Economic Times.

Web References:-

https://www.investindia.gov.in/sector/pharmaceuticals

https://pharmaceuticals.gov.in/policy/pharmaceutical-policy-2002

Similar Articles

<< < 20 21 22 23 24 25 26 27 28 29 > >> 

You may also start an advanced similarity search for this article.